RT Journal Article
SR Electronic
T1 Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1205
OP 1211
DO 10.2967/jnumed.119.236000
VO 61
IS 8
A1 Caroline Rousseau
A1 David M. Goldenberg
A1 Mathilde Colombié
A1 Jean-Charles Sébille
A1 Philippe Meingan
A1 Ludovic Ferrer
A1 Pierre Baumgartner
A1 Evelyne Cerato
A1 Damien Masson
A1 Mario Campone
A1 Aurore Rauscher
A1 Vincent Fleury
A1 Catherine Labbe
A1 Alain Faivre Chauvet
A1 Jean-Sebastien Fresnel
A1 Claire Toquet
A1 Jacques Barbet
A1 Robert M. Sharkey
A1 Loic Campion
A1 Françoise Kraeber-Bodéré
YR 2020
UL http://jnm.snmjournals.org/content/61/8/1205.abstract
AB This prospective study evaluated the imaging performance of a novel pretargeting immunologic PET (immuno-PET) method in patients with human epidermal growth factor receptor 2 (HER2)–negative, carcinoembryonic antigen (CEA)–positive metastatic breast cancer, compared with CT, bone MRI, and 18F-FDG PET. Methods: Twenty-three patients underwent whole-body immuno-PET after injection of 150 MBq of 68Ga-IMP288, a histamine-succinyl-glycine peptide given after initial targeting of a trivalent anti-CEA, bispecific, antipeptide antibody. The gold standards were histology and imaging follow-up. Tumor SUVs (SUVmax and SUVmean) were measured, and tumor burden was analyzed using total tumor volume and total lesion activity. Results: The total lesion sensitivity of immuno-PET and 18F-FDG PET were 94.7% (1,116/1,178) and 89.6% (1,056/1,178), respectively. Immuno-PET had a somewhat higher sensitivity than CT or 18F-FDG PET in lymph nodes (92.4% vs. 69.7% and 89.4%, respectively) and liver metastases (97.3% vs. 92.1% and 94.8%, respectively), whereas sensitivity was lower for lung metastases (48.3% vs. 100% and 75.9%, respectively). Immuno-PET showed higher sensitivity than MRI or 18F-FDG PET for bone lesions (95.8% vs. 90.7% and 89.3%, respectively). In contrast to 18F-FDG PET, immuno-PET disclosed brain metastases. Despite equivalent tumor SUVmax, SUVmean, and total tumor volume, total lesion activity was significantly higher with immuno-PET than with 18F-FDG PET (P = 0.009). Conclusion: Immuno-PET using anti-CEA/anti-IMP288 bispecific antibody, followed by 68Ga-IMP288, is a potentially sensitive theranostic imaging method for HER2-negative, CEA-positive metastatic breast cancer patients and warrants further research.